Showing 20 of 84 recruiting trials for “non-hodgkin-lymphoma”
Enrolling by InvitationNCT07474051 ↗
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
👨⚕️ Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Dec 2025View details ↗
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
👨⚕️ Christopher J Melani, ECOG-ACRIN Cancer Research Group📍 70 sites📅 Started Oct 2025View details ↗
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
👨⚕️ Narendranath Epperla, MD, MS, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Oct 2025View details ↗
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
👨⚕️ Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Sep 2025View details ↗
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
👨⚕️ Evgeny E Zvonkov, MD, PhD, National Medical Research Center for Hematology📍 1 site📅 Started Jul 2025View details ↗
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
👨⚕️ Dehui Zou, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started May 2025View details ↗
KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
👨⚕️ Andrey Kaprin, FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation📍 1 site📅 Started Apr 2025View details ↗
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
👨⚕️ Alessandra Tucci, Dr.ssa, UO Ematologia, ASST Spedali Civili di Brescia, Piazzale Spedali Civili, 1, 25123 Brescia, Italia📍 20 sites📅 Started Apr 2025View details ↗
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
👨⚕️ Yazeed Sawalha, Ohio State University Comprehensive Cancer Center📍 2 sites📅 Started Apr 2025View details ↗
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
👨⚕️ Ryan Lynch, MD, Fred Hutch/University of Washington Cancer Consortium📍 5 sites📅 Started Mar 2025View details ↗
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Page 1 of 5Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →